Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Guardant Health Inc (NQ: GH )

16.22 -0.84 (-4.92%)
Streaming Delayed Price Updated: 11:11 AM EDT, Apr 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Guardant Health Inc

< Previous 1 2 3 4 5 Next >
Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360® CDx and Guardant360 TissueNext™ as Companion Diagnostics for Taletrectinib in Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
From Guardant Health Inc.
Via Business Wire
Magistrate Judge Issues Favorable Recommendation Regarding Guardant Health’s Motion to Dismiss Lawsuit Brought by Illumina
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
From Guardant Health, Inc.
Via Business Wire
Guardant Health introduces Guardant GalaxyTM suite of advanced AI analytics to enhance its portfolio of cancer tests and accelerate biomarker discovery
From Guardant Health, Inc.
Via Business Wire
Guardant Health receives FDA approval for Guardant360® CDx as companion diagnostic for Menarini Group’s ORSERDU™ for treatment of patients with ESR1 mutations in ER+, HER2- advanced or metastatic breast cancer
From Guardant Health, Inc.
Via Business Wire
Guardant Health and The Royal Marsden NHS Foundation Trust partner on highly anticipated TRACC Part C trial to use Guardant Reveal™ blood test to help guide treatment decisions in colorectal cancer
From Guardant Health, Inc.
Via Business Wire
Guardant Health to showcase new data at ASCO GI 2023 demonstrating utility of its blood tests for patients with gastrointestinal cancers
From Guardant Health, Inc.
Via Business Wire
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2022 Results
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Participate in the 41st Annual J.P. Morgan Healthcare Conference
From Guardant Health, Inc.
Via Business Wire
Guardant Health and Susan G. Komen® Partner to Develop Clinical Studies to Identify Early-Stage Breast Cancer Patients Who May Benefit From Additional Monitoring or Therapy
From Guardant Health, Inc.
Via Business Wire
Guardant Health announces positive results from pivotal ECLIPSE study evaluating a blood test for the detection of colorectal cancer
From Guardant Health, Inc.
Via Business Wire
Guardant Health Announces Collaboration With AstraZeneca to Develop Companion Diagnostic to Identify Patients With ESR1-mutated Metastatic Breast Cancer
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Showcase New Data at San Antonio Breast Cancer Symposium 2022 Demonstrating Utility of Its Blood Tests for Advanced-stage Breast Cancer Patients
From Guardant Health, Inc.
Via Business Wire
Guardant Health Reports Third Quarter 2022 Financial Results
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Report Third Quarter 2022 Financial Results on November 3, 2022
From Guardant Health, Inc.
Via Business Wire
Guardant Health Introduces GuardantINFINITY™ Smart Liquid Biopsy for Research Use to Help Bring New Cancer Therapies to Patients Sooner
From Guardant Health, Inc.
Via Business Wire
Guardant Health to showcase new data at ESMO 2022 demonstrating utility of its portfolio of blood tests for advanced-stage cancer patients
From Guardant Health, Inc.
Via Business Wire
Guardant Health Expands Strategic Collaboration With Merck KGaA, Darmstadt, Germany, to Help Accelerate Development of Precision Oncology Therapeutics
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Participate in the Morgan Stanley Global Healthcare Conference
From Guardant Health, Inc.
Via Business Wire
Guardant Health Expands Use of Guardant Reveal™ Liquid Biopsy Test for Residual Disease Detection and Recurrence Monitoring to Include Early-Stage Breast and Lung Cancers
From Guardant Health, Inc.
Via Business Wire
Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for Daiichi Sankyo and AstraZeneca’s ENHERTU® for Treatment of NSCLC Patients With Activating HER2 Mutations
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Participate in the UBS Genomics 2.0 and MedTech Innovations Summit Conference
From Guardant Health, Inc.
Via Business Wire
Guardant Health and Blueprint Medicines present real-world data identifying EGFR C797X mutation as most common resistance mechanism to osimertinib therapy at IASLC 2022 World Conference on Lung Cancer
From Guardant Health, Inc.
Via Business Wire
Guardant Health Announces New Data from its Portfolio of Blood Tests and GuardantINFORM™ Real-World Clinical-Genomic Platform at IASLC 2022 World Conference on Lung Cancer
From Guardant Health, Inc.
Via Business Wire
Guardant Health Reports Second Quarter 2022 Financial Results
From Guardant Health, Inc.
Via Business Wire
Guardant Health Receives Medicare Coverage for Guardant Reveal™ Test
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Report Second Quarter 2022 Financial Results on August 4, 2022
From Guardant Health, Inc.
Via Business Wire
Steve E. Krognes Joins Guardant Health Board of Directors
From Guardant Health, Inc.
Via Business Wire
Guardant Health Completes Purchase of Guardant Health AMEA Joint Venture
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Participate in Upcoming June Investor Conferences
From Guardant Health, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.